William Blair analyst Matt Phipps maintained a Hold rating on Kezar Life Sciences (KZR – Research Report) today. The company’s shares closed ...

Stock analysts at William Blair lowered their Q1 2025 EPS estimates for shares of AMN Healthcare Services in a report issued ...

Analysts at William Blair issued their Q1 2026 earnings estimates for Enovix in a report issued on Thursday, February 20th. William Blair analyst J. Dorsheimer expects that the company will earn ...

Fintel reports that on February 21, 2025, William Blair downgraded their outlook for CACI International (NYSE:CACI) from ...

William Blair downgrades Booz Allen, CACI International, Leidos, Parsons and General Dynamics on the heightened risk of ...

Fintel reports that on February 21, 2025, William Blair downgraded their outlook for Booz Allen Hamilton Holding (NYSE:BAH) ...

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

William Blair analyst Arjun Bhatia maintained a Buy rating on Radcom (RDCM – Research Report) today. The company’s shares opened today at ...

We recently compiled a list of the 10 AI News and Ratings Making Waves on Wall Street. In this article, we are going to take ...

Fintel reports that on February 21, 2025, William Blair downgraded their outlook for General Dynamics (WBAG:GEDY) from Outperform to Market Perform. There are 2,727 funds or institutions reporting ...

Fintel reports that on February 21, 2025, William Blair downgraded their outlook for General Dynamics (LSE:0IUC) from Outperform to Market Perform. As of January 29, 2025, the average one-year ...